Jacobs Levy Equity Management, Inc Shattuck Labs, Inc. Transaction History

Jacobs Levy Equity Management, Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 16, 2023	SELL	$1.42 - $3.16 $25,869 - $57,568	-18,218 Reduced 19.52%	75,113 $114,000
Q2 2023 Aug 14, 2023	SELL	$2.52 - $3.66 $74,982 - $108,903	-29,755 Reduced 24.17%	93,331 $291,000
Q1 2023 May 15, 2023	SELL	$2.5 - $4.72 $37,975 - $71,696	-15,190 Reduced 10.99%	123,086 $361,000
Q4 2022 Feb 14, 2023	BUY	$1.96 - $3.26 $30,566 - $50,839	15,595 Added 12.71%	138,276 $318,000
Q3 2022 Nov 15, 2022	SELL	$2.6 - $5.52 $177,608 - $377,076	-68,311 Reduced 35.77%	122,681 $331,000
Q2 2022 Aug 15, 2022	SELL	$2.7 - $4.59 $29,710 - $50,508	-11,004 Reduced 5.45%	190,992 $775,000
Q1 2022 May 16, 2022	BUY	$4.22 - $8.89 $788,874 - $1.66 Million	186,937 Added 1241.36%	201,996 $861,000
Q4 2021 Feb 14, 2022	BUY	$8.36 - $21.08 $125,893 - $317,443	15,059 New	15,059 $128,000

28.8M

300

1.2K

Ticker STTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,382,000
Market Cap $46.6M
Description
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is ...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.